As­traZeneca grabs an FDA OK for its new leukemia drug, to be mar­ket­ed as Lu­mox­i­ti

As­traZeneca $AZN just got an­oth­er boost for its on­col­o­gy port­fo­lio. The FDA has whisked through a fast OK for the an­ti-CD22 drug mox­e­tu­momab pa­su­do­tox for rare cas­es of hairy cell leukemia.

The green light comes three years af­ter As­traZeneca first steered to­ward Phase III af­ter see­ing some promis­ing ear­ly da­ta. Their big biotech group Med­im­mune had man­aged the work on this drug, which came out of the NCI.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER